Dexcom's Bet Beyond Diabetes
Share
Dexcom CEO Jake Leach joined Bloomberg Open Interest to explain why continuous glucose monitors are becoming much bigger than diabetes devices. He says GLP-1 drugs are actually boosting CGM adoption and defends the company's growth outlook. He also lays out Dexcom's push into mainstream metabolic health and wellness.
More from Australia
Woodside Energy cuts 500 jobs to slash costs by US$570M
NSW panel recommends 26 stricter data centre rules
Top End Energy applies to surrender permit EP 153
Neuren Pharmaceuticals upgrades full year guidance
Vicinity Centres places earnings guidance under review
Resources & Energy expands Menzies Project by 69%
